Apterna Therapeutics

Apterna is a private UK-based preclinical biotechnology company developing precision-delivered, non-viral RNA therapeutics for liver and brain diseases. Its strategy is centered on organ-targeted delivery, with a liver-focused platform using GalNAc-based hepatocyte delivery and a brain-focused platform designed for systemic transport across the blood-brain barrier. The lead program, APX-101, is being advanced toward first-in-human readiness for severe liver disease and advanced hepatic impairment, with the goal of restoring liver function and enabling access to existing therapies or surgery. Additional programs address metabolic liver disease, brain metastases, and broader CNS indications. The company positions itself as a build-to-partner platform biotech with translational roots in Imperial College London and City of Hope.